Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract CancerSecond FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors
- InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in ChinaICP-B161 delivers an extended half‑life, which allows for less frequent dosing and supports subcutaneous administration.
- First Tracks Biotherapeutics IncFirst Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.
- Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically significant 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.82; 95% CI 0.73-0.93; p<0.01)
- AbbVieNew SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseaseCompanies: AbbVieNew Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups New open-label extension analyses demonstrate sustained endoscopic outcomes over...
- Sebela PharmaceuticalsSebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 MeetingKey Highlights: Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. phase 3 clinical trial. Detailed analysis from the randomized, double-blind, placebo-controlled Phase 3...
- Monteverde & Associates PCSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Option Care Health, Inc. (NASDAQ: OPCH)Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The...
- Claris Biotherapeutics Releases Positive CSB-001 Clinical Proof-of-Concept Data in Limbal Stem Cell Deficiency at AAO 2026 Annual Meeting41% of CSB-001 treated eyes gained ≥15 letters compared to 0% in the non-treatment arm
- Beyond Cholesterol Numbers: Dr. Wallace Brucker Brings AI-Powered Cardiac Plaque Screening to Las Vegas Executives at LV Longevity LabLV Longevity Lab is a Las Vegas-based longevity and optimization medical practice led by Dr. Wallace Brucker, MD.
- AnX RoboticaAnX Robotica Highlights Documented ProScan AI Workflow Performance from Submission to FDASeparate FDA submissions report mean small-bowel capsule review-time reductions of 88.6% with ProScan-assisted reading and 24.7% with a recently cleared comparator AI-assisted workflow. — AnX Robotica today highlighted the documented results of...
- The Rosen Law Firm PAROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Church of Scientology InternationalChurch of Scientology International's Scientology Network Marks World Mental Health Day with CCHR Documentary MarathonOn World Mental Health Day, October 10, Scientology Network presents a marathon event spotlighting the Citizens Commission on Human Rights (CCHR). The program features CCHR's mission to expose psychiatric industry corruption and combat human...